Paraoxonase activity and genotype predispose to successful aging

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 61, Issue 6, 2006, Pages 541-546

  Marchegiani, Francesca ^a   Marra, Maurizio ^a   Spazzafumo, Liana ^a   James, Richard W ^b   Boemi, Massimo ^a   Olivieri, Fabiola ^a   Cardelli, Maurizio ^a   Cavallone, Luca ^a   Bonfigli, Anna Rita ^a   Franceschi, Claudio ^a,c  

^a INRCA   (Italy)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; DNA; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ALLELE; ARTICLE; CODON; ENZYME ACTIVITY; FEMALE; GENE; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL;

EID: 33745223635     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/61.6.541     Document Type: Article

References (36)

1. Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE. Structural organization of the human PON1 gene. Genomics. 1996;35:586-589.
2. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res. 2003;37:77-83.
3. La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact. 1999;119-120:379-388.
4. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
5. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
6. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52;598-608.
7. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62-66.
8. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 1999;9:745-753.
9. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond). 2004;107:435-447.
10. Lawlor DA, Day IN, Gaunt TR, et al. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet. 2004;5:17.
11. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol. 1998;9:319-324.
12. Ombres D, Pannitteri G, Montali A, et al. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol. 1998;18:1611-1616.
13. Paolisso G, Manzella D, Tagliamonte MR, et al. The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. J Clin Endocrinol Metab. 2001;86:1078-1082.
14. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol. 2000;20:2441-2447.
15. Jarvik GP, Hatsukami TS, Carlson C, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol. 2003;23:1465-1471.
16. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001;21:1451-1457.
17. Bonafe M, Marchegiani F, Cardelli M, et al. Genetic analysis of paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet. 2002;10:292-296.
18. Rea IM, McKeown PP, McMaster D, et al. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp Gerontol. 2004;39:629-635.
19. Franceschi C, Olivieri F, Marchegiani F, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev. 2005;126:351-361.
20. Ligthart GJ, Corberand JX, Fournier C, et al. Admission criteria for immunogerontological studies in man: the Senieur protocol. Mech Ageing Dev. 1984;28:47-55.
21. Franceschi C, Motta L, Valensin S, et al. Do men and women follow different trajectories to reach extreme longevity? Italian Multicenter Study on Centenarians (IMUSCE). Aging (Milano). 2000;12:77-84.
22. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
23. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193-199.
24. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet. 1988;43:230-238.
25. Blatter Garin MC, Abbot C, Messmer S, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549-554.
26. Guo SW, Thompson EA. A Monte Carlo method for combined segregation and linkage analysis. Am J Hum Genet. 1992;51:1111-1126.
27. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002;162:2333-2341.
28. Passarino G, Calignano C, Vallone A, et al. Male/female ratio in centenarians: a possible role played by population genetic structure. Exp Gerontol. 2002;37:1283-1289.
29. Nevin DN, Zambon A, Furlong CE, et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol. 1996;16:1243-1249.
30. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact. 1999;119-120:429-438.
31. Bonafe M, Olivieri F, Cavallone L, et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol. 2001;31:2357-2361.
32. Olivieri F, Bonafe M, Cavallone L, et al. The -174 C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol. 2002;37:309-314.
33. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol. 2004;39:59-66.
34. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892-904.
35. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617-1624.
36. Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11:412-419.